Table 2.
Biomarkers determination
| Primary tumor (n = 70) | Metastases (n = 49) | Clinical practicea (n = 102) | |
|---|---|---|---|
| No. (%) | No. (%) | No. (%) | |
| ER status | |||
| < 1% | 3 (4.3) | 0 | 2 (2.0) |
| ≥ 1% | 65 (92.9) | 49 (100) | 100 (98.0) |
| Unknown | 2 (2.8) | 0 | 0 |
| PgR status | |||
| < 1% | 10 (14.3) | 12 (24.5) | 22 (21.6) |
| ≥ 1% | 58 (82.9) | 37 (75.5) | 80 (78.4) |
| Unknown | 2 (2.8) | 0 | 0 |
| Ki67 status | |||
| < 20% | 39 (55.7) | 30 (61.2) | 63 (61.8) |
| ≥ 20% | 27 (38.6) | 17 (34.7) | 38 (37.2) |
| Unknown | 4 (5.7) | 2 (4.1) | 1 (1) |
| HER2 status | |||
| Negative | 57 (81.4) | 41 (83.7) | 88 (86.3) |
| Positive | 10 (14.3) | 7 (14.3) | 14 (13.7) |
| Unknown | 3 (4.3) | 1 (2) | 0 |
| AR status | |||
| < 1% | 5 (7.1) | 12 (24.5) | 17 (16.7) |
| ≥ 1% | 65 (92.9) | 37 (75.5) | 85 (83.3) |
| < 10% | 7 (10.0) | 19 (38.8) | 26 (25.5) |
| ≥ 10% | 63 (90.0) | 30 (61.2) | 76 (74.5) |
Abbreviation: ER estrogen receptor, PgR progesterone receptor, AR androgen receptor, HER2 human epidermal growth factor receptor 2
abiomarker measured on metastatic sample when a metastatic biopsy was available, or on primary tumor when biopsy of metastasis had not been performed